Index. Hematol Oncol Clin N Am 19 (2005) Note: Page numbers of article titles are in boldface type.

Transcription

1 Hematol Oncol Clin N Am 19 (2005) Index Note: Page numbers of article titles are in boldface type. A Abciximab, as an antiplatelet agent, Acute coronary syndromes, use of antiplatelet drugs in, ximelagatran for prevention of cardiovascular events after, 79 Acute ischemic stroke, thrombolytic therapy for, current clinical practice, Alopecia, as complication of heparin Alteplase, structure, function, and procoagulant effect of, Anaphylaxis, in acute reaction to heparin, 40 Angina, chronic, use of antiplatelet drugs in, Anticoagulant therapy, with unfractionated heparin, 1 4 with vitamin K antagonists, Anticoagulation, of central venous catheters in clinical practice, Antiplatelet agents, adverse effects of, bleeding complications, with aspirin, 107 clinical use of, in acute coronary syndrome, in cerebrovascular disease, 106 in chronic angina, in percutaneous coronary intervention, in peripheral occlusive arterial disease, drugs currently in use, aspirin, indirect-acting drugs, phosphodiesterase inhibitors, platelet glycoprotein IIb/IIIa complex inhibitors, thienopyridines, 93 future agents for, research on pathogenesis of thrombosis and, research on physiology and, resistance to, 108 Antithrombotic therapy, antiplatelet agents, adverse effects of, clinical use of, drugs currently in use, future agents for, research on pathogenesis of thrombosis and, research on physiology and, resistance to, 108 central venous catheter-related thrombosis in cancer patients, anticoagulation of, in clinical practice, direct thrombin inhibitors, 77 80, as alternative to vitamin K antagonist therapy, ximelagatran, current status and clinical use of, argatroban, bivalirudin, 131 melagatran and ximelagatran, recombinant hirudin (lepirudin), /05/$ see front matter D 2005 Elsevier Inc. All rights reserved. doi: /s (04) hemonc.theclinics.com

2 204 INDEX role and use for rational anticoagulation, current status and clinical use of, indirect agents, current status and clinical use, indirect versus direct inhibitors, 124 rationale and function of, 126 role of thrombin in thrombogenesis, thrombolytic therapy, current clinical practice, agents for, structure, function, and procoagulant effects, cerebrovascular thrombosis, complications of, miscellaneous disorders, 170 myocardial infarction, overview of, 148 peripheral arterial thrombosis, venous thromboembolism, unfractionated heparin, low molecular weight heparins, and pentasaccharides, 1 51 mechanism of action, pharmacology, and clinical use, pentasaccharides (fondaparinux), unfractionated heparin, 1 4 side effects and adverse reactions to, acute heparin reaction (anaphylaxis?), 40 alopecia, 44 altered liver function tests, 44 bleeding, heparin and eosinophilia, 44 heparin-associated osteoporosis, heparin-induced thrombocytopenia, heparin-related dermal reactions, hyperkalemia, hypoaldosteronism, and metabolic disorders, 44 in patients with prosthetic heart valves, 45 in pregnancy, priapism, 44 vitamin K antagonists, adverse effects of, alternatives to, for long-term treatment, pharmacology of, Ardeparin, 5 8, 10 Argatroban, as a direct thrombin inhibitor, as an antiplatelet agent, Arixtra. See Fondaparinux. Arterial disease. See Peripheral arterial thrombosis. Aspirin, as an antiplatelet agent, adverse effects of, 107 Atrial fibrillation, antiplatelet therapy in, 106 ximelagatran for stroke prevention in patients with, 79 B Bivalirudin, as a direct thrombin inhibitor, 131 as an antiplatelet agent, Bleeding complications, of antiplatelet therapy, of heparin therapy, of pentasaccharide therapy, of vitamin K antagonist therapy, C Cancer patients, catheter-related thrombosis in, anticoagulation of, in clinical practice, Cardiovascular events, ximelagatran for prevention of, after acute coronary syndromes, 79 Catheter-related thrombosis, in cancer patients, anticoagulation of, in clinical practice,

3 INDEX 205 Central venous catheters, thrombosis of, in cancer patients, anticoagulation of, in clinical practice, Cerebrovascular disease, current clinical practice for antithrombotic therapy for, antiplatelet drugs for, 106 current clinical practice in antithrombotic therapy for, in acute ischemic stroke, Certoparin, 5 6, 11, 14 Cilostazol, as an antiplatelet agent, 95 Clexane. See Enoxaparin. Clivarin. See Reviparin. Clopidogrel, as antiplatelet agent, 93 Collagen, inhibitors of interaction with platelets, future applications of, 110 Congestive heart failure, antiplatelet therapy in, 107 Coronary syndromes, acute, use of antiplatelet drugs in, ximelagatran for prevention of cardiovascular events after, 79 Coumarins. See Warfarin and Vitamin K antagonists. D Dalteparin, 5 12, 14, 16 versus ximelagatran for treatment of acute venous thromboembolism, 78 Deep vein thrombosis, central venous catheter-related, thrombolytic therapy in, current clinical practice, Dermal reactions, heparin-related, Dipyridamole, as an antiplatelet agent, Direct thrombin inhibitors, as alternative to vitamin K antagonist therapy, ximelagatran, role and use for rational anticoagulation, current status and clinical use of, argatroban, bivalirudin, 131 melagatran and ximelagatran, recombinant hirudin (lepirudin), indirect agents, current status and clinical use, indirect versus direct inhibitors, 124 rationale and function of, 126 role of thrombin in thrombogenesis, E Embolism. See Pulmonary embolism. Enoxaparin, 5 11, 13 14, 20 21, adverse effects in pregnant women with prosthetic heart valves, teratogenic effects of, Eosinophilia, related to heparin Eptifibatide, as an antiplatelet agent, 94 Exanta, see Ximelagatran F Fibrin sheath formation, catheter-related thrombosis due to, Fluxum. See Panaparin. Fondaparinux, as an antiplatelet drug, mechanism of action, pharmacology, and clinical use, Fragmin. See Dalteparin. Fraxiparin. See Nadroparin. G Generic drugs, low molecular weight heparins, development of, 53 68

4 206 INDEX Glycoprotein Ib inhibitors, as future antiplatelet agents, Glycoprotein IIb/IIIa complex inhibitors, as antiplatelet agents, H Heart valves, prosthetic, adverse reactions to heparins in pregnant women with, Heparin, as an antiplatelet agent, clinical use as an indirect thrombin inhibitor, weight, for long-term treatment of venous thromboembolism, in prevention of central venous catheter-related deep venous thrombosis, mechanism of action, pharmacology, and clinical use, low molecular weight, 4 23 pentasaccharides (fondaparinux), unfractionated, 1 4 side effects and adverse reactions to unfractionated heparin, low molecular weight heparin, and pentasaccharide, acute heparin reaction (anaphylaxis?), 40 alopecia, 44 altered liver function tests, 44 bleeding, dermal reactions related to, eosinophilia, 44 heparin-induced thrombocytopenia, hyperkalemia, hypoaldosteronism, and metabolic disorders, 44 in patients with prosthetic heart valves, 45 in pregnancy, osteoporosis associated with, priapism, 44 Heparin-induced thrombocytopenia, treatment of, 38 Hirudin, as an antiplatelet agent, recombinant (lepirudin), as a direct thrombin inhibitor, Hirulog. See Bivalirudin. Hyperkalemia, related to heparin Hypoaldosteronism, related to heparin I Indeparin. See Ardeparin. Indirect thrombin inhibitors, clinical use of heparin and warfarin as, versus direct thrombin inhibitors, 124 Infection, due to central venous catheter thrombosis, 188 Innohep. See Tinzaparin. Intraluminal thrombosis, of central venous catheters, 186 Ischemic stroke, acute, thrombolytic therapy for, current clinical practice, L Lepirudin, as a direct thrombin inhibitor, Liver function tests, altered, with long-term heparin administration, 44 Logiparin. See Tinzaparin. Lovenox. See Enoxaparin. Low molecular weight heparin, as an antiplatelet agent, Low molecular weight heparins, development of generic, for long-term treatment of venous thromboembolism, mechanism of action, pharmacology, and clinical use, 4 23 M Melagatran, as a direct thrombin inhibitor, Metabolic disorders, related to heparin Myocardial infarction, thrombolytic therapy in, current clinical practice, delivery of reperfusion therapy, facilitated percutaneous coronary intervention, 156 primary percutaneous coronary intervention, thrombolysis versus primary percutaneous coronary intervention, N Nadroparin, 5 6

5 INDEX 207 Nonsteroidal anti-inflammatory drugs (NSAIDs), aspirin, as an antiplatelet agent, Normiflo. See Ardeparin. O Osteoporosis, heparin-associated, Overanticoagulation, due to vitamin K antagonist therapy, See also Bleeding complications. P Panaparin, 5 6 Patent foramen ovale, antiplatelet therapy in, 107 Pentasaccharides (fondaparinux), bleeding as complication of therapy with, mechanism of action, pharmacology, and clinical use, thrombocytopenia induced by, Percutaneous coronary intervention, antiplatelet therapy in, ADP receptor antagonists, aspirin, 101 platelet glycoprotein IIb/IIIa inhibitors in, in myocardial infarction, delivery of reperfusion therapy, facilitated, 156 primary, versus thrombolysis, Peripheral arterial thrombosis, current clinical practice, antiplatelet agents for, 106 Phosphodiesterase inhibitors, as antiplatelet agents, Physiology, in research on antiplatelet drugs, Plasminogen activator, recombinant (r-pa), structure, function, and procoagulant effect of, Postphlebitic syndrome, due to central venous catheter thrombosis, Prenancy, adverse reactions to enoxaparin in pregnant women with prosthetic heart valves, Priapism, as complication of heparin Prosthetic heart valves, adverse reactions to heparins in pregnant women with, Pulmonary embolism, due to central venous catheter thrombosis, 189 thrombolytic therapy in, current clinical practice, R Recombinant plasminogen activator (r-pa), structure, function, and procoagulant effect of, Recombinant tissue plasminogen activator (rt-pa), structure, function, and Refludan. See Lepirudin. Resistance, to antiplatelet drugs, 108 Reteplase, structure, function, and Reviparin, 5 6 S Sandoparin. See Certoparin. Skin necrosis, coumarin-induced, 75 heparin-related, Streptokinase, structure, function, and Stroke, acute ischemic, thrombolytic therapy for, current clinical practice, Stroke prevention, ximelagatran for, in patients with atrial fibrillation, 79 T Tenecteplase, structure, function, and Teratogenic effects, of enoxaparin, Thienopyridines, as antiplatelet agents, 93 Thrombin, role in thrombogenesis, Thrombocytopenia, heparin-induced, treatment of, 38 pentasaccharide-induced, Thrombogenesis, role of thrombin in, Thrombolytic agents, structure, function, and

6 208 INDEX Thrombolytic therapy current clinical practice, cerebrovascular thrombosis, complications of, miscellaneous disorders, 170 myocardial infarction, peripheral arterial thrombosis, venous thromboembolism, See also Antithrombotic therapy. Thrombosis, pathogenesis of, in research on antiplatelet drugs, Thromboxane receptor antagonists, as future antiplatelet agents, 109 Thromboxane synthase inhibitors, as future antiplatelet agents, 109 Ticlopidine, as antiplatelet agent, 93 Tinzaparin, 5 8, 10, 15, 16 Tirofiban, as an antiplatelet agent, 94 Tissue plasminogen activator, recombinant (rt-pa), structure, function, and U Unfractionated heparin, mechanism of action, pharmacology, and clinical use, 1 4 Urokinase, structure, function, and V Venous thromboembolism, thrombolytic therapy in, acute, ximelagatran versus dalteparin for, 78 current clinical practice, deep vein thrombosis, pulmonary embolism, Vitamin K antagonists, anticoagulation therapy with, adverse effects of, alternatives to, for long-term treatment, pharmacology of, W Warfarin, clinical use as an indirect thrombin inhibitor, low-dose, in prevention of central venous catheter-related deep venous thrombosis, pharmacokinetics and pharmacodynamics of, See also Vitamin K antagonists. X Ximelagatran, as a direct thrombin inhibitor, as an antiplatelet agent, for initial and long-term treatment of thrombotic disorders, for long-term treatment of venous thromboembolism, 78 for prevention of cardiovascular events after acute coronary syndromes, for stroke prevention in patients with atrial fibrillation, 79 for treatment of acute venous thromboembolism, 78